Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Uncovering Giant Magnetic Anisotropy in Co(II) Single-Ion Magnets via Combined Ab Initio and Machine-Learning Approaches.

Inorganic chemistry·2026
Same author

Multifunctional Guest-Hosting Triple-Stranded Helicates: From Anion Recognition to Quantum Information Applications.

Accounts of chemical research·2026
Same author

Proteomic Landscape of H<sub>2</sub>S-Releasing Peptide Mediated Neuroprotection in Traumatic Brain Injury.

Journal of proteome research·2026
Same author

A Rare Case of Anti-CASPR2 Encephalitis as the Presenting Manifestation of Hepatitis B Virus Infection.

Annals of Indian Academy of Neurology·2026
Same author

The RNA-binding protein Quaking is essential for cardiac homeostasis and function by regulating Morf4l2 splicing.

Journal of molecular and cellular cardiology·2025
Same author

Targeting Triple Negative Breast Cancer with a Dinuclear Copper(II) Thiocarbohydrazone Complex: Efficacy Evaluation and Cellular Response.

ACS omega·2025
Same journal

Corrigendum to "Targeting PD-L1 and disrupting Siglec-9 cooperatively potentiate macrophage phagocytosis of breast cancer via a trispecific macrophage engager (TriME)" [Biomed. Pharmacother. 200 (2026), 119609].

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2026
Same journal

Targeted attenuation of liver fibrosis using microbubble-enhanced protease-activated receptor 1 chimeric antigen receptor T cells.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2026
Same journal

Euphol targets key oncogenic processes and promotes chemoprevention in organoid and In Vivo models of colorectal cancers.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2026
Same journal

CAR-T cell therapy and oncolytic viruses: A synergic approach for advanced GI cancers.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2026
Same journal

Corrigendum to "Antidiabetic sitagliptin influences tissue regeneration by affecting progenitor cells" [Biomed. Pharmacother. 189 (2025) 118279].

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2026
Same journal

Corrigendum: "Zebrafish as a model to study inflammation: A tool for drug discovery" [Biomed. Pharmacother. 144 (2021) 112310].

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2026
See all related articles

Related Experiment Video

Updated: Jan 17, 2026

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

14.3K

Targeting RUNX3/PARP1 signaling ameliorates colorectal cancer cachexia.

Abinash Swain1, Pinaki Prasad Mahapatra2, Abhishek Nirwan3

  • 1Cell Death Research Laboratory, Endocrinology Division, CSIR-Central Drug Research Institute, B.S. 10/1, Sector-10, Jankipuram Extension Lucknow, Uttar Pradesh 226031, India.

Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie
|September 19, 2025
PubMed
Summary
This summary is machine-generated.

Colorectal cancer cachexia causes muscle loss. Researchers found that inhibiting Poly (ADP-ribose) polymerases 1 (PARP1) with Olaparib reversed muscle atrophy by targeting RUNX3, offering new treatment possibilities.

Keywords:
Cancer cachexiaMuRF1OlaparibPARP1RUNX3muscle atrophy

More Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.8K
A Multiplexed Luciferase-based Screening Platform for Interrogating Cancer-associated Signal Transduction in Cultured Cells
10:13

A Multiplexed Luciferase-based Screening Platform for Interrogating Cancer-associated Signal Transduction in Cultured Cells

Published on: July 3, 2013

11.6K

Related Experiment Videos

Last Updated: Jan 17, 2026

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

14.3K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.8K
A Multiplexed Luciferase-based Screening Platform for Interrogating Cancer-associated Signal Transduction in Cultured Cells
10:13

A Multiplexed Luciferase-based Screening Platform for Interrogating Cancer-associated Signal Transduction in Cultured Cells

Published on: July 3, 2013

11.6K

Area of Science:

  • Oncology
  • Muscle Biology
  • Molecular Medicine

Background:

  • Colorectal cancer cachexia involves significant muscle atrophy, impacting patient morbidity and mortality.
  • Current treatments for cancer cachexia have limitations including toxicity and low response rates.
  • The role of Poly (ADP-ribose) polymerases 1 (PARP1) in muscle atrophy is not fully understood.

Purpose of the Study:

  • To investigate the role of PARP1 in regulating colorectal cancer cachexia.
  • To explore the underlying molecular mechanisms involving the PARP inhibitor Olaparib.
  • To determine if targeting PARP1 can mitigate muscle atrophy in colorectal cancer.

Main Methods:

  • Utilized both in vitro and in vivo models of colorectal cancer cachexia.
  • Administered the PARP inhibitor Olaparib to assess its effects on muscle atrophy.
  • Investigated the regulatory pathway involving transcription factor RUNX3, PARP1, and MuRF1 expression.

Main Results:

  • Pharmacological inhibition of PARP1 with Olaparib effectively reversed muscle atrophy parameters.
  • Identified RUNX3 as a regulator of MuRF1 expression via PARP1-mediated PARylation in colorectal cancer cachexia.
  • Demonstrated that RUNX3 binding to the MuRF1 promoter activates its transcription.

Conclusions:

  • This study is the first to show RUNX3 PARylation's critical role in muscle atrophy regulation within colorectal cancer cachexia.
  • The RUNX3/PARP1 signaling pathway presents a promising target for novel colorectal cancer cachexia management strategies.